| Market Cap | 577.05M | P/E | 6.82 | EPS this Y | - | Ern Qtrly Grth | 526.60% |
| Income | 84.86M | Forward P/E | 8.87 | EPS next Y | - | 50D Avg Chg | 13.00% |
| Sales | 166.7M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 44.00% |
| Dividend | N/A | Price/Book | 2.94 | EPS next 5Y | 25.00% | 52W High Chg | -1.00% |
| Recommedations | 2.70 | Quick Ratio | 2.08 | Shares Outstanding | 103.23M | 52W Low Chg | 124.00% |
| Insider Own | 7.58% | ROA | 8.22% | Shares Float | 86.76M | Beta | 0.56 |
| Inst Own | 68.21% | ROE | 57.33% | Shares Shorted/Prior | 4.20M/2.77M | Price | 5.59 |
| Gross Margin | 85.98% | Profit Margin | 50.91% | Avg. Volume | 3,352,473 | Target Price | - |
| Oper. Margin | 22.27% | Earnings Date | Nov 1 | Volume | 2,107,479 | Change | -0.09% |
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.
| Piper Sandler | Neutral | Feb 15, 22 |
| HC Wainwright & Co. | Neutral | Jan 21, 22 |
| HC Wainwright & Co. | Neutral | Nov 4, 21 |
| HC Wainwright & Co. | Buy | Aug 5, 21 |
| HC Wainwright & Co. | Buy | Mar 11, 21 |
| SunTrust Robinson Humphrey | Buy | Dec 18, 19 |
| SunTrust Robinson Humphrey | Buy | Mar 20, 19 |
| H.C. Wainwright | Buy | May 23, 18 |
| Seaport Global | Buy | Jan 26, 18 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Vollins James | See Remarks See Remarks | Feb 04 | Sell | 3.6 | 18,541 | 66,748 | 9,872 | 02/08/22 |
| - | - - | Aug 10 | Option | 1.47 | 45,000 | 66,150 | 4,700,689 | 08/10/21 |
| - | - - | May 13 | Buy | 3.22 | 300,000 | 966,000 | 4,655,689 | 05/13/21 |
| Vollins James | See Remarks See Remarks | Feb 08 | Sell | 4.07 | 12,136 | 49,394 | 02/08/21 | |
| Coelho Mary Theresa | See Remarks See Remarks | Feb 02 | Option | 0 | 10,190 | 34,079 | 02/02/21 | |
| Coelho Mary Theresa | See Remarks See Remarks | Feb 02 | Sell | 3.87 | 3,460 | 13,390 | 30,619 | 02/02/21 |